The bio-pathways report was very critical—and FPInnovations was the lead on the findings—but what helped us out was understanding the true value from the forest sector. I think we've completed that. I think we know mostly what we can make. Again, that work, though, was done specifically in our facilities, the economic conditions that were there.
Now we just have to convince the market to accept it. We need more partnerships. CelluForce is a great example, but it took them three years to be able to sell NCC with Schlumberger. We need to accelerate that. We need to be able to do it right off the bat. If we can make it, and you can absorb it, then let's work together.